n response to rising drug costs, advocacy groups in the U.K. are pushing the government to make medicines that are developed with taxpayer funds more accessible. And in a new report, they suggest the U.K. government take steps that activists in the U.S. have also begun to demand.

Specifically, the U.K. groups argue the government ought to require drug makers to disclose R&D costs and licensing terms for medicines that are discovered with taxpayer money. Licenses should include provisions that somehow guarantee patient access. And prices should not automatically be linked to R&D costs incurred by companies.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • If failing memory serves, when ABT – now AbbVee – acquired the company that had the ‘rights’ to Humira, Miles White had to cough up $6+ Billion [2001] USD to purchase said entity. Mayhaps the claw back should be from them?

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.